USPTO's Rescission Of Controversial Patent Rules

Law360, New York (November 04, 2009, 9:59 AM ET) -- The U.S. Patent and Trademark Office recently announced that it is rescinding its highly controversial new patent rules and that a motion to dismiss and vacate the district court decision on these regulations litigated in Tafas v. Dudas (now Tafas v. Kappos) will be filed jointly with one of the plaintiffs-appellees, GlaxoSmithKline (GSK).[1]

According to the new director of the USPTO, David Kappos, the rationale for rescinding these regulations is that “(t)he USPTO should incentivize innovation, develop rules that are responsive to its applicants’ needs and...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers